Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.47 |
| ▸ | EP300 | Q09472 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.43 |
| ▸ | WNT1 | P04628 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | CLK3 | P49761 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22998076 | 0.87 | EP300 (0.48) | MAP4K1EP300MAPK1PIK3CAMAPK8 | |
| SCHEMBL30238470 | 0.87 | MAPK1 (0.47) | MAP4K1EP300MAPK1PIK3CAMAPK8 | |
| SCHEMBL30662090 | 0.81 | MAPK1 (0.65) | MAP4K1EP300MAPK1PIK3CAMAPK8 | |
| SCHEMBL30238347 | 0.80 | GSK3B (0.51) | EP300DYRK1AGSK3BWNT1ABL1 | |
| SCHEMBL30238422 | 0.79 | STING1 (0.50) | MAP4K1EP300MAPK1PIK3CAMAPK8 | |
| SCHEMBL22998769 | 0.77 | GSK3B (0.48) | MAP4K1EP300DYRK1AGSK3BWNT1 | |
| SCHEMBL28486101 | 0.76 | GSK3B (0.45) | MAP4K1EP300MAPK1PIK3CAMAPK8 | |
| SCHEMBL28483799 | 0.76 | EP300 (0.44) | MAP4K1EP300MAPK1PIK3CAMAPK8 | |
| SCHEMBL21426449 | 0.76 | MAPK1 (0.64) | EP300MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL30662136 | 0.75 | IKBKE (0.46) | MAP4K1MAPK1DYRK1AGSK3BWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-07 | — | — | US | disclosed |
| CN-111918863-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-11584737-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584737-B2 | Heterocyclic compound | CDK12, CDK1, CDK15 | MAP4K1 120/4885EP300 896/4885MAPK1 151/4885 |
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | CDK1, CDK12, CDK15 | MAP4K1 154/4885EP300 1401/4885MAPK1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.